1 Questions to the Subcommittee 1.What criteria do you recommend to TPSAC for selecting the initial list of H/PH constituents?

Slides:



Advertisements
Similar presentations
Regulation of Consumer Tests in California AAAS Meeting June 1-2, 2009 Beatrice OKeefe Acting Chief, Laboratory Field Services California Department of.
Advertisements

Regulation of amounts of various constituents in cigarette smoke.
Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
Determining the Significant Aspects
Validation of screening methods (2002/657/EC)
Effectiveness Evaluation for Production Drugs Crystal Groesbeck, Ph.D Division of Production Drugs.
1 Method Selection and Development l Initial Considerations n What does the method need to do? 3 What analyte/s need to be assayed? 3 What range or concentration.
U.S. EPA Region 9’s New Response Action Levels 02 October 2014 Derral Van Winkle, P.G. NAVFAC Southwest, Environmental Restoration Program Manager.
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
1 Preliminary Information Concerning the Establishment of a List of Harmful and Potentially Harmful Tobacco Product Constituents Before the FDA Tobacco.
CHEMICAL CARCINOGENS CHEMICAL CARCINOGENS. What is a Chemical Carcinogen?  Any chemical compound which has been shown to cause cancer in humans or in.
Carcinogen Classification Criteria Patricia Richter Ph.D., DABT Tobacco Products Scientific Advisory Committee June 8, 2010.
Analytical Chemistry.
Tobacco Lesson 1. Tobacco has ____________ effects on almost all body systems. cigarette lungs cancer tobacco harmful crave oxygen.
World Health Organization
The Policy-Making Process ESD 11 December 8, 2000.
Patricia Richter Ph.D., DABT Centers for Disease Control and Prevention Office on Smoking and Health Tobacco Product Constituents Subcommittee June 8-9,
NSF/ANSI STANDARD 61 FRAMEWORK FOR RISK ASSESSMENTS For use by Toxicology Sub-committee only Please do not copy or distribute.
What Do Toxicologists Do?
Principles of New Animal Drug Effectiveness: An Overview
 2011 Johns Hopkins Bloomberg School of Public Health Regulation of Tobacco Products Mitch Zeller, JD Pinney Associates.
Multi-Agency Radiological Laboratory Analytical Protocols Manual: MARLAP Presentation to the Radiation Advisory Committee/Science Advisory Board April.
WHO Prequalification Program Workshop, Kiev, Ukraine, June 25-27,2007.
Kyiv, TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE & BIOEQUIVALENCE Validation of Analytical Methods Used For Bioequivalence.
Safeguarding Animal Health 1 Proposed BSE Comprehensive Rule: A New Approach to BSE Rulemaking Dr. Christopher Robinson Assistant Director, NCIE BSE Comprehensive.
Validation of Analytical Method
Kenneth E. Warner University of Michigan University of Iowa November 15, 2002 Technology, Policy, and the Future of Nicotine Addiction.
Life Cycle Overview & Resources. Life Cycle Management What is it? Integrated concept for managing goods and services towards more sustainable production.
Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.
The following minimum specified ranges should be considered: Drug substance or a finished (drug) product 80 to 120 % of the test concentration Content.
Analytical considerations
 2011 Johns Hopkins Bloomberg School of Public Health Jonathan M. Samet, MD, MS Director, USC Institute for Global Health Professor and Flora L. Thornton.
Method Validation and Verification: An Overview Patricia Hanson, Biological Administrator I Florida Department of Agriculture and Consumer Services, Food.
 2011 Johns Hopkins Bloomberg School of Public Health Building Blocks for Effective Tobacco Product Regulation Section B.
How to Select a Test Method Marlene Moore Advanced Systems, Inc. June 15, 2010.
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation Fundamentals of Pharmacology for Veterinary Technicians 1 Submitted by Callie Parr.
Forging Partnerships on Emerging Contaminants November 2, 2005 John Vandenberg Associate Director for Health National Center for Environmental Assessment.
Preliminary Thoughts on Evaluating Harm Reduction Claims Based on the Mass SAB Experience 2003 National Conference on Tobacco or Health David Burns MD.
1 of 39 The EPA 7-Step DQO Process Step 3 - Identify Inputs (45 minutes) Presenter: Sebastian Tindall Day 2 DQO Training Course Module 3.
Reclaimed Wastewater Quality Criteria, Standards, and Guidelines
EXPERIMENTAL EPIDEMIOLOGY
FDA – TPSAC – June 8-9, 2010 Preliminary Information Concerning the Establishment of a List of Harmful and Potentially Harmful Tobacco Product Constituents:
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
1 Questions to the Subcommittee 1.What criteria do you recommend to TPSAC for selecting the H/PH constituents in tobacco products or tobacco smoke (which.
FDA Regulation: The Impact on Product Development and Reporting Monica Graves Director – Marketing Operations Oversight RAI Services Company May 18, 2009.
FDA Advisory Committee Tobacco Constituents Subcommittee June 8 & 9, 2010 Gaithersburg, Maryland Recommendations for Measurement of Toxic Tobacco Constituents.
 Routine viral diagnostics: indirect and direct detection of viruses. ◦ Indirect detection: serological tests; ◦ Direct detection:  Viral antigens;
1 Harmful/Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Tobacco Product Constituents Subcommittee Meeting July 7, 2010 Corinne.
SEMINAR ON PRESENTED BY BRAHMABHATT BANSARI K. M. PHARM PART DEPARTMENT OF PHARMACEUTICS AND PHARMACEUTICAL TECHNOLGY L. M. COLLEGE OF PHARMACY.
Strategies for regulation of cigarette emissions The WHO product regulatory approach Nigel Gray David Burns For TobReg Working Group 1 in Conjunction with.
means to “TO CHECK OR PROVE THE VALIDITY OF” According to FDA – “ The goal of validation is to establish a documented evidence which provides a high degree.
Regulation of: - amounts of various constituents in cigarette smoke - information on packages regarding smoke constituents - smokefree tobacco products.
HOLD-TIME STUDIES.
Use of Borates in Swimming Pools: Consideration of Health Effects
STABILITY ?.
VALIDATION OF PHARMACEUTICAL PROCESSES
Analytical Chemistry.
World Health Organization
Results of the analysis in tobacco
Substance Use and Abuse
WHO Technical Report Series, No. 953, 2009
The Toxic Substances Control Act of 1976 (TSCA)
Practical clinical chemistry
This teaching material has been made freely available by the KEMRI-Wellcome Trust (Kilifi, Kenya). You can freely download,
METHOD VALIDATION: AN ESSENTIAL COMPONENT OF THE MEASUREMENT PROCESS
Single-Case Designs.
יוסי שדמתי רק איכות מניהול סיכונים לאימות ותיקוף תהליכי הרכבה From Risk Management to Processes Validation יוסי.
International Initiatives and the U.S. HPV Challenge Program
Quality Assessment The goal of laboratory analysis is to provide the accurate, reliable and timeliness result Quality assurance The overall program that.
Quality guidelines on impurities
Presentation transcript:

1 Questions to the Subcommittee 1.What criteria do you recommend to TPSAC for selecting the initial list of H/PH constituents?

2 CTP’s Understanding of the Criteria to be Recommended to TPSAC Identified by International Agency for Research on Cancer (IARC) as: –Sufficient evidence in humans or sufficient evidence in animals and strong mechanistic data in humans (Group 1) –Limited evidence in humans and sufficient evidence in animals (Group 2A) –Limited evidence in humans and less than sufficient evidence in animals (Group 2 B) Identified by Environmental Protection Agency (EPA) or the Agency for Toxic Substances and Disease Registry (ATSDR) as a respiratory or cardiac toxicant Identified by the California EPA as a reproductive or developmental toxicant One smokeless constituent included because it is banned in food

3 CTP’s Understanding of the Criteria to be Recommended to TPSAC Evidence for potential abuse liability –Evidence of CNS activity –Animal discrimination –Conditioned Place Preference (CPP) –Animal self-administration –Human self-administration –Drug “liking” Study –Withdrawal (physical dependence) Some constituents added on the basis of several published peer-reviewed studies suggesting cardiac or respiratory toxicity, or addiction

4 Questions to the Subcommittee (continued) 2. What H/PH constituents do you recommend TPSAC include on the initial list of H/PH constituents in tobacco products or tobacco smoke?

6 Questions to the Subcommittee (continued) 3.Which smoking regimen or regimens does the Subcommittee recommend to TPSAC be used to measure H/PH constituents Understanding that no method will truly represent the consumer exposure ISO – historical perspective Health Canada Intensive – determine performance of the product

7 4.What analytical parameters (e.g., accuracy, reproducibility, repeatability, throughput) do you recommend to TPSAC as those FDA should consider in comparing methods? -Accuracy, reproducibility (between labs), repeatability (within a lab), and sensitivity (limit of detection, particularly relevant to level of constituent) of methods -Use of standard reference materials -> basis for comparison -Determine range of reproducibility and repeatability (both within and across laboratories) -Obtain temporary baseline until more data is available -Reproducibility and repeatability may be relatively more important than accuracy (in absence of a reference material) -Confirmation of accuracy and method by external lab -Ability to get information on multiple analytes from single method (throughput – economic consideration) -Flexibility over time – processes will evolve

8 Questions to the Subcommittee (continued) 5. What considerations do you recommend to TPSAC as those FDA should take into account when developing a sampling plan for tobacco products? For example: –How should the number of replicates be determined? –How often should tobacco products be tested? –Should the products be analyzed immediately after they are manufactured or stored under certain environmental conditions to simulate shelf time? –Are there other important considerations regarding tobacco product collection and storage?

Question 5 Need to gain understanding of the products as experienced by the consumer (sampling at the retail level) –Will include variation due to temporal, climatic, regional factors At least annual sampling (perhaps more often for smokeless) As information is accumulated, may prove testable with simpler sampling scheme (e.g. from point of manufacture) Information already available from other countries, tobacco industry, NCI smokeless TOBPRAC study in progress (should be considered before final decision)

10 Questions to the Subcommittee (continued) 6. Are there other important scientific information / parameters that the Subcommittee recommends to TPSAC as those FDA should consider in measuring H/PH constituent levels?

Normalization (from June meeting) Data should be collected in a way that allows normalization of reported constituent quantities as follows: Cigarettes: per nicotine, per stick, per gram total particulate material (allows comparison across products), per gram of tar Smokeless Tobacco: per nicotine, per gram of dry weight, per portion, per tin/container of product

Question 6 Extraction procedures – same protocol may produce different results, dependent on tobacco matrix Measure pH over time (both in smoke and smokeless) – relates to addiction potential (at this point in time, no specific method has been recommended for smoke) Surveillance of constituents over time Information on things that may influence testing –Ventilation, porosity, pH, blend, weight/stick or pouch, puff number, cut width, moisture, filter type, additives –Characteristics of cigarettes should be integrated with smoke yield